This 2020 lab study investigated sulforaphane’s effects on an Alzheimer’s disease enzyme:
“BACE1 is the rate-limiting enzyme responsible for the production of Aβ [amyloid-beta] from APP [amyloid precursor protein]. Both the expression level and activity of this enzyme are aberrantly elevated in the brains of patients with AD.
Sulforaphane exhibited six times more potent activity against BACE1 compared to well-known positive controls including resveratrol and quercetin. Sulforaphane presented selective and non-competitive BACE1 inhibitory activity with low off-target inhibition.
Molecular docking simulation was used to analyze whether the compound can reach the target enzyme to produce the biological effect safely and interact with the targeted sites.
The blood–brain barrier (BBB) is constituted by neurovascular units that contain endothelial cells. A previous study reported that gavage administration of sulforaphane penetrated BBB in its intact structure and accumulated in brain tissues with a maximum increase and disappearance after 15 min and 2 h, respectively.”
https://www.mdpi.com/2072-6643/12/10/3026/htm ” Discovery of Sulforaphane as a Potent BACE1 Inhibitor Based on Kinetics and Computational Studies”